Luminex Revenue Growth Rates (LMNX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Luminex Corporation  (NASDAQ: LMNX)
 

LMNX's Revenue Growth by Quarter and Year

Luminex's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LMNX Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 110.69
FY 110.69

LMNXs Annual Revenue
Luminex's Revenue in the fiscal year 2020 $ 417.40 millions
Luminex's Revenue in the fiscal year 2019 $ 334.64 millions
Luminex's Revenue in the fiscal year 2018 $ 315.82 millions
Luminex's Revenue in the fiscal year 2017 $ 306.57 millions
Luminex's Revenue in the fiscal year 2016 $ 270.64 millions




LMNX Revenue first quarter 2021 Y/Y Growth Comment
Luminex Corporation achieved in the first quarter 2021, above Company average Revenue growth of 22.42% year on year, to $ 110.69 millions.

Looking into first quarter 2021 results within Medical Equipment & Supplies industry 32 other companies have achieved higher Revenue growth. While Luminex Corporation' s Revenue rise of 22.42% ranks overall at the positon no. 828 in the first quarter 2021.


LMNX Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - 23.08 % 11.55 % 3.75 %
3rd Quarter September - 34.82 % 8.59 % -2.28 %
2nd Quarter June - 31.86 % 4.37 % 4.08 %
1st Quarter March 22.42 % 9.72 % -0.3 % 6.27 %
FY   - 24.73 % 5.96 % -

Financial Statements
Luminex's first quarter 2021 Revenue $ 110.69 millions LMNX's Income Statement
Luminex's first quarter 2020 Revenue $ 90.42 millions Quarterly LMNX's Income Statement


LMNX Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - 5.03 % 15.04 % 11.98 %
3rd Quarter September - -3.16 % -5.29 % -8.96 %
2nd Quarter June - 21.12 % 0.79 % -3.73 %
1st Quarter March -0.63 % -0.09 % 1.58 % 5.7 %
FY (Year on Year)   - 24.73 % 5.96 % -


Back to LMNX Growth rate Comparisons >> Back to LMNX Growth rate Comparisons >>


Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #33
Healthcare Sector #165
Overall #828

Revenue Y/Y Growth Statistics
High Average Low
61.49 % 10.69 % -5.38 %
(Dec 31 2020)   (Dec 31 2015)
Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #33
Healthcare Sector #165
Overall #828
Revenue Y/Y Growth Statistics
High Average Low
61.49 % 10.69 % -5.38 %
(Dec 31 2020)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Luminex's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
15.03 % 1.44 % -24.26 %
(Dec 31 2019)  


LMNX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2021 Luminex Corporation disclosed decrease in Revenue from the fourth quarter by -0.63% to $ 110.69 millions, from $ 111.39 millions achived in the previous reporting period.

But that's not important problem, as Luminex's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 128 other companies have achieved higher Revenue quarter on quarter growth. While Luminex's Revenue growth quarter on quarter, overall rank is 3187.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #129
Healthcare Sector #445
Overall #3187
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #129
Healthcare Sector #445
Overall #3187
Revenue Q/Q Growth Statistics
High Average Low
15.03 % 1.44 % -24.26 %
(Dec 31 2019)  


LMNX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2021 Luminex Corporation disclosed decrease in Revenue from the fourth quarter by -0.63% to $ 110.69 millions, from $ 111.39 millions achived in the previous reporting period.

But that's not important problem, as Luminex's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 128 other companies have achieved higher Revenue quarter on quarter growth. While Luminex's Revenue growth quarter on quarter, overall rank is 3187.


Luminex's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)
Cumulative Revenue 12 Months Ending $ 437.66 $ 417.40 $ 396.50 $ 369.12 $ 342.65
Y / Y Revenue Growth (TTM) 27.73 % 24.73 % 21.9 % 15.7 % 8.58 %
Year on Year Revenue Growth Overall Ranking # 1529 # 442 # 418 # 1753 # 1678
Seqeuential Revenue Change (TTM) 4.85 % 5.27 % 7.42 % 7.72 % 2.4 %
Seq. Revenue Growth (TTM) Overall Ranking # 2021 # 161 # 414 # 1394 # 0


Cumulative Revenue growth Comment
Luminex saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 27.73% year on year, to $ 438 millions if the fiscal year would have ended in Mar 31 2021.
Luminex's trailing twelve months Revenue growth was higher than company's average 11.86% and higher than 24.73% growth in Dec 31 2020.
But from twelve months ended Dec 31 2020 rise was beneth at 4.85 % from $417.4 millions achieved in the period from Dec 31 2020 to Mar 31 2020.
We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at11.86%.
The momentum is even more impressive from twelve months ended Dec 31 2020 exhibited at 4.85 % increase from $417.4 millions in the period from Dec 31 2020 to Mar 31 2020.

In the Healthcare sector 272 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 442 to 1529.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 74
Healthcare Sector # 273
Overall # 1529

Revenue TTM Y/Y Growth Statistics
High Average Low
37.21 %
 11.86 %
1.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 74
Sector # 323
S&P 500 # 2021
Cumulative Revenue growth Comment
Luminex saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 27.73% year on year, to $ 438 millions if the fiscal year would have ended in Mar 31 2021.
Luminex's trailing twelve months Revenue growth was higher than company's average 11.86% and higher than 24.73% growth in Dec 31 2020.
But from twelve months ended Dec 31 2020 rise was beneth at 4.85 % from $417.4 millions achieved in the period from Dec 31 2020 to Mar 31 2020.
We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at11.86%.
The momentum is even more impressive from twelve months ended Dec 31 2020 exhibited at 4.85 % increase from $417.4 millions in the period from Dec 31 2020 to Mar 31 2020.

In the Healthcare sector 272 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 442 to 1529.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 74
Healthcare Sector # 273
Overall # 1529

Revenue TTM Y/Y Growth Statistics
High Average Low
37.21 %
11.86 %
1.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 74
Sector # 323
S&P 500 # 2021




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LMNX's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2021
Scienture Holdings Inc 38.57%$ 38.574 millions
Biolife Solutions Inc 38.52%$ 38.522 millions
Catalent Inc 38.48%$ 38.483 millions
Regeneron Pharmaceuticals Inc 38.32%$ 38.316 millions
Pro dex Inc 37.98%$ 37.976 millions
Supernus Pharmaceuticals inc 37.86%$ 37.858 millions
Genedx Holdings Corp 37.61%$ 37.608 millions
Sientra Inc 37.23%$ 37.231 millions
Signify Health Inc 36.67%$ 36.674 millions
West Pharmaceutical Services Inc 36.46%$ 36.460 millions
Abbott Laboratories35.34%$ 35.335 millions
Phenomex Inc 35.20%$ 35.201 millions
Capforce Inc 34.49%$ 34.490 millions
Veru Inc 34.17%$ 34.168 millions
China Pharma Holdings Inc33.70%$ 33.698 millions
Healthlynked Corp33.49%$ 33.491 millions
Adamas Pharmaceuticals Inc33.35%$ 33.354 millions
Merus N v 32.52%$ 32.519 millions
Talphera Inc 32.38%$ 32.383 millions
Novocure Limited32.28%$ 32.277 millions
Delcath Systems Inc 31.97%$ 31.973 millions
Orthopediatrics Corp31.22%$ 31.218 millions
Icad Inc31.21%$ 31.212 millions
Castle Biosciences Inc 30.97%$ 30.974 millions
Waters Corporation30.89%$ 30.887 millions
Bruker Corporation30.83%$ 30.825 millions
Axonics Inc 30.72%$ 30.716 millions
Rapt Therapeutics Inc 30.70%$ 30.695 millions
Harrow Inc 30.68%$ 30.685 millions
Elutia Inc 30.63%$ 30.630 millions


About Luminex Revenue Growth Rates (LMNX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.